AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease

AbbVie Inc. (NYSE: ABBV ) is one of the best undervalued stocks to invest in right now.
ascopubs.org

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) Patients with stage IIIB-IVM1c unresectable ...
Business Wire

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Lupus Foundation of America

New Research Explores Efficacy of Belimumab and Rituximab Combination Therapy for Systemic Lupus Erythematosus

In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...
The American Journal of Managed Care

Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis

The RELIEVE trial assesses remibrutinib's efficacy and safety in generalized myasthenia gravis, involving 180 participants in a 6-month double-blind study. Remibrutinib has shown a positive safety ...